Enzychem Lifesciences Corp
183490
Company Profile
Business description
Enzychem Lifesciences Corp develops and produces APIs and functional health foods. It manufactures veterinary medicine tablets, capsules, syrups, injections, ointments, solutions for the diagnosis and prevention of various diseases. The company is also developing drugs to treat chemotherapy-induced neutropenia, chemo-radiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, and others.
Contact
27 Gangnamdae-ro Seocho-gu
10th Floor, aT Center
Seoul135-280
KORT: +82 262137131
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
130
Stocks News & Analysis
stocks
Finding yield on the ASX
The ASX, known for its yield appeal is at its lowest level in 20 years. Here’s why, and what investors should do.
stocks
ExxonMobil earnings: Continued execution, on track for 2030 targets
We’ve raised our fair value estimate of Exxon stock.
stocks
Disney earnings: No big surprises in solid results
Growth in areas critical to the firm’s future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,174.30 | 18.10 | 0.20% |
| CAC 40 | 8,181.17 | 54.64 | 0.67% |
| DAX 40 | 24,797.52 | 258.71 | 1.05% |
| Dow JONES (US) | 49,407.66 | 515.19 | 1.05% |
| FTSE 100 | 10,341.56 | 118.02 | 1.15% |
| HKSE | 26,775.57 | 611.54 | -2.23% |
| NASDAQ | 23,592.11 | 130.29 | 0.56% |
| Nikkei 225 | 54,154.47 | 1,499.29 | 2.85% |
| NZX 50 Index | 13,442.52 | 30.08 | 0.22% |
| S&P 500 | 6,976.44 | 37.41 | 0.54% |
| S&P/ASX 200 | 8,882.50 | 16.20 | 0.18% |
| SSE Composite Index | 4,015.75 | 0.00 | 0.00% |